A systematic review of association between use of hair products and benign and malignant gynecological conditions.
Autor: | Farooq H; Aga Khan University Medical College, Karachi, Pakistan., Mhatre P; Seth G.S. Medical College and K.E.M. Hospital, Mumbai, India., Aggarwal R; Dayanand Medical College and Hospital, Ludhiana, Punjab, India., Robinson MT; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Joseph E; Informationist Services, Welch Medical Library, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Segars J; Division of Reproductive Sciences & Women's Health Research, Department of Gynecology & Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Singh B; Division of Reproductive Sciences & Women's Health Research, Department of Gynecology & Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: bsingh10@jhmi.edu. |
---|---|
Jazyk: | angličtina |
Zdroj: | European journal of obstetrics, gynecology, and reproductive biology [Eur J Obstet Gynecol Reprod Biol] 2024 Apr; Vol. 295, pp. 160-171. Date of Electronic Publication: 2024 Feb 14. |
DOI: | 10.1016/j.ejogrb.2024.02.012 |
Abstrakt: | Hair products often contain chemicals like para-phenylenediamine (PPD) and endocrine-disrupting chemicals (EDCs); giving rise to concerns about the possible adverse effects such as hormonal disturbances and carcinogenicity. The objective of this systematic review was to evaluate the association between the use of different hair products and benign and malignant gynecological conditions. Studies were identified from three databases including PubMed, Embase, and Scopus, and evaluated in accordance with PRISMA guidelines. The risk of bias was assessed using the Newcastle-Ottawa Scale. A total of 17 English-language studies met the inclusion criteria. Associations of hair relaxer or hair dye use with breast and ovarian cancer were observed in at least one well-designed study, but these findings were not consistent across studies. Further sub-analysis showed 1.08 times (95 % CI: 1.01-1.15) increased risk of breast cancer in females with permanent hair dye use. Chang et al. reported strong association between uterine cancer risk and hair relaxer use (HR 1.8, 95 % CI: 1.12-2.88), with no observed association with hair dye use. Studies conducted by Wise et al. and James-Todd et al. for benign gynecological conditions; including uterine leiomyoma (IRR 1.17, 95 % CI: 1.06-1.30), early onset of menarche (RR 1.4, 95 % CI: 1.1-1.9), and decreased fecundability (FR 0.89, 95 % CI: 0.81-0.98) revealed positive associations with hair relaxer use, but these findings were based on small sample sizes. In summary, the available evidence regarding personal use of hair products and gynecological conditions is insufficient to determine whether a positive association exists. Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024 Elsevier B.V. All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |